<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">Sarcopenia was first described in 1988 as the age-related decline of skeletal muscle mass .</segment>
<segment id="2" parent="1002" relname="span">In the last decade , several international groups have developed operational definitions of sarcopenia</segment>
<segment id="3" parent="2" relname="elaboration">which incorporate assessments of muscle function in addition to muscle mass in sarcopenia case-finding guidelines .</segment>
<segment id="4" parent="1005" relname="attribution">Nonetheless , recent changes to these recommendations demonstrate</segment>
<segment id="5" parent="1006" relname="span">that there is significant work</segment>
<segment id="6" parent="5" relname="elaboration">to be done</segment>
<segment id="7" parent="1007" relname="span">in order to achieve an international consensus on the methods</segment>
<segment id="8" parent="7" relname="purpose">to diagnose and treat sarcopenia in clinical settings .</segment>
<segment id="9" parent="1010" relname="span">Indeed ,</segment>
<segment id="10" parent="1012" relname="span">while sarcopenia is now recognised with its own International Classification of Diseases , 10th Revision , Clinical Modification</segment>
<segment id="11" parent="10" relname="restatement">( ICD-10-CM )</segment>
<segment id="12" parent="1013" relname="span">code</segment>
<segment id="13" parent="12" relname="restatement">( M62.84 ) ,</segment>
<segment id="14" parent="15" relname="attribution">few health care professionals know</segment>
<segment id="15" parent="1015" relname="span">how to diagnose it ,</segment>
<segment id="16" parent="1016" relname="contrast">include it as part of their clinical practice ,</segment>
<segment id="17" parent="1016" relname="contrast">or even recognise it as a disease , .</segment>
<segment id="18" parent="1019" relname="span">This Special Issue of the Journal of Clinical Medicine was established with a view</segment>
<segment id="19" parent="1020" relname="joint">to increase clinician awareness of the important clinical consequences of sarcopenia</segment>
<segment id="20" parent="1020" relname="joint">and improve understanding of diagnosis and treatment strategies .</segment>
<segment id="21" parent="1023" relname="span">Computed tomography</segment>
<segment id="22" parent="21" relname="elaboration">( CT )</segment>
<segment id="23" parent="1022" relname="same_unit">provides precise estimates of muscle quality</segment>
<segment id="24" parent="25" relname="concession">and so may be useful for case-finding in sarcopenia ,</segment>
<segment id="25" parent="1024" relname="span">but barriers to this method include high costs , lack of availability and ionising radiation doses .</segment>
<segment id="26" parent="1028" relname="span">Ultrasound represents a potentially cost-effective , accessible and safe method</segment>
<segment id="27" parent="26" relname="elaboration">of measuring muscle quality</segment>
<segment id="28" parent="1029" relname="span">and Harris-Love and colleagues demonstrate in this special issue</segment>
<segment id="29" parent="1031" relname="span">that rectus femoris echogenicity</segment>
<segment id="30" parent="29" relname="elaboration">assessed by ultrasound is significantly correlated with intra- and inter-muscular adipose tissue estimates from CT ,</segment>
<segment id="31" parent="1030" relname="joint">and has similar associations with muscle function and cardiometabolic outcomes .</segment>
<segment id="32" parent="1033" relname="span">For clinicians without requisite expertise or access to equipment</segment>
<segment id="33" parent="32" relname="purpose">to perform muscle mass assessments ,</segment>
<segment id="34" parent="1035" relname="attribution">it is possible</segment>
<segment id="35" parent="1035" relname="span">that questionnaires can be useful</segment>
<segment id="36" parent="35" relname="elaboration">in identifying patients at risk of sarcopenia .</segment>
<segment id="37" parent="1039" relname="span">The SarQoL®</segment>
<segment id="38" parent="37" relname="elaboration">( Sarcopenia and Quality of Life ) ,</segment>
<segment id="39" parent="1040" relname="span">is a validated quality of life</segment>
<segment id="40" parent="39" relname="restatement">( QoL )</segment>
<segment id="41" parent="1042" relname="span">questionnaire</segment>
<segment id="42" parent="41" relname="elaboration">which can discriminate sarcopenic and non-sarcopenic patients</segment>
<segment id="43" parent="1041" relname="joint">and has already been translated into several languages .</segment>
<segment id="44" parent="1044" relname="span">In this issue , a study on the validation of a Polish version of the SarQoL® is described ,</segment>
<segment id="45" parent="1045" relname="span">highlighting the potential utility of this instrument</segment>
<segment id="46" parent="45" relname="elaboration">for identifying individuals at risk of sarcopenia , as well as its impact on QoL , across a number of countries worldwide .</segment>
<segment id="47" parent="1047" relname="preparation">Physical function assessments are also simple</segment>
<segment id="48" parent="1047" relname="joint">to perform in clinical settings</segment>
<segment id="49" parent="1049" relname="span">and may be most appropriate</segment>
<segment id="50" parent="1050" relname="span">to identify sarcopenia cases in obese older adults</segment>
<segment id="51" parent="50" relname="elaboration">who ,</segment>
<segment id="52" parent="1052" relname="joint">owing to their larger muscle mass , may generally exceed cut-off points for low muscle mass .</segment>
<segment id="53" parent="1053" relname="span">Mesinovic and colleagues demonstrate associations between the metabolic syndrome and poorer muscle function</segment>
<segment id="54" parent="1054" relname="span">despite the generally larger muscle size in overweight and obese older individuals ,</segment>
<segment id="55" parent="54" relname="elaboration">indicating accelerated loss of muscle quality is common in this population .</segment>
<segment id="56" parent="1057" relname="concession">Sarcopenia is generally considered a disease of ageing</segment>
<segment id="57" parent="1057" relname="span">but there is no doubt</segment>
<segment id="58" parent="1058" relname="span">that risk</segment>
<segment id="59" parent="58" relname="elaboration">of developing sarcopenia is increased by numerous medical conditions .</segment>
<segment id="60" parent="1059" relname="joint">Moreover , the presence of sarcopenia appears to consistently impact on prognosis of those with existing comorbidities .</segment>
<segment id="61" parent="62" relname="attribution">Indeed , the review by Han and colleagues demonstrates</segment>
<segment id="62" parent="1061" relname="span">that sarcopenia is associated with increased progression of chronic disease , postoperative complications , length of hospital stay , all-cause mortality and cognitive impairment .</segment>
<segment id="63" parent="1063" relname="span">The effects of sarcopenia on cognitive impairment are supported by an original study of community-dwelling older adults</segment>
<segment id="64" parent="1064" relname="span">residing in rural areas of Korea</segment>
<segment id="65" parent="66" relname="attribution">which reported</segment>
<segment id="66" parent="1065" relname="span">that physical frailty was significantly associated with poor cognitive function .</segment>
<segment id="67" parent="1067" relname="joint">Liver disease is also associated with weight loss and physical frailty ,</segment>
<segment id="68" parent="1069" relname="attribution">and a population-based study reported</segment>
<segment id="69" parent="1070" relname="span">that non-alcoholic fatty liver disease was more common in Korean adults with low muscle mass</segment>
<segment id="70" parent="69" relname="elaboration">determined by CT ,</segment>
<segment id="71" parent="1069" relname="same_unit">regardless of their obesity status .</segment>
<segment id="72" parent="73" relname="attribution">Similarly , a study of Japanese patients with chronic liver disease reported</segment>
<segment id="73" parent="1072" relname="span">that 50 % had low muscle mass , either alone or combined with low muscle strength .</segment>
<segment id="74" parent="1073" relname="span">Interestingly , low serum zinc concentration was an independent predictor of sarcopenia in these patients</segment>
<segment id="75" parent="1074" relname="span">suggesting zinc supplementation warrants further investigation as a strategy</segment>
<segment id="76" parent="75" relname="purpose">to prevent muscle declines in chronic liver disease .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1003" relname="background"/>
<group id="1003" type="multinuc" parent="1001" relname="span"/>
<group id="1004" type="span" parent="1003" relname="joint"/>
<group id="1005" type="span" parent="1004" relname="span"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1007" type="span" parent="1006" relname="purpose"/>
<group id="1009" type="multinuc" parent="1003" relname="joint"/>
<group id="1010" type="span" parent="1009" relname="same_unit"/>
<group id="1011" type="multinuc" parent="9" relname="concession"/>
<group id="1012" type="span" parent="1011" relname="same_unit"/>
<group id="1013" type="span" parent="1011" relname="same_unit"/>
<group id="1014" type="multinuc" parent="1009" relname="same_unit"/>
<group id="1015" type="span" parent="1014" relname="same_unit"/>
<group id="1016" type="multinuc" parent="1014" relname="same_unit"/>
<group id="1018" type="span" parent="1003" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="span"/>
<group id="1020" type="multinuc" parent="18" relname="purpose"/>
<group id="1021" type="span" parent="1019" relname="elaboration"/>
<group id="1022" type="multinuc" parent="1021" relname="span"/>
<group id="1023" type="span" parent="1022" relname="same_unit"/>
<group id="1024" type="span" parent="1022" relname="result"/>
<group id="1026" type="span" parent="1003" relname="joint"/>
<group id="1027" type="multinuc" parent="1026" relname="span"/>
<group id="1028" type="span" parent="1027" relname="same_unit"/>
<group id="1029" type="span" parent="1027" relname="same_unit"/>
<group id="1030" type="multinuc" parent="28" relname="elaboration"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1027" relname="elaboration"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="span" parent="1032" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1037" type="multinuc" parent="1003" relname="joint"/>
<group id="1038" type="multinuc" parent="1037" relname="same_unit"/>
<group id="1039" type="span" parent="1038" relname="same_unit"/>
<group id="1040" type="span" parent="1038" relname="same_unit"/>
<group id="1041" type="multinuc" parent="1037" relname="same_unit"/>
<group id="1042" type="span" parent="1041" relname="joint"/>
<group id="1043" type="span" parent="1003" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="44" relname="elaboration"/>
<group id="1046" type="span" parent="1044" relname="elaboration"/>
<group id="1047" type="multinuc" parent="1046" relname="span"/>
<group id="1048" type="multinuc" parent="1047" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="span" parent="49" relname="purpose"/>
<group id="1051" type="multinuc" parent="1048" relname="joint"/>
<group id="1052" type="multinuc" parent="1051" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="53" relname="concession"/>
<group id="1055" type="multinuc" parent="1051" relname="joint"/>
<group id="1056" type="span" parent="1055" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="span"/>
<group id="1058" type="span" parent="57" relname="elaboration"/>
<group id="1059" type="multinuc" parent="1055" relname="joint"/>
<group id="1060" type="multinuc" parent="1059" relname="joint"/>
<group id="1061" type="span" parent="1060" relname="joint"/>
<group id="1062" type="multinuc" parent="1060" relname="joint"/>
<group id="1063" type="span" parent="1062" relname="joint"/>
<group id="1064" type="span" parent="63" relname="elaboration"/>
<group id="1065" type="span" parent="64" relname="elaboration"/>
<group id="1066" type="multinuc" parent="1062" relname="joint"/>
<group id="1067" type="multinuc" parent="1066" relname="joint"/>
<group id="1068" type="span" parent="1067" relname="joint"/>
<group id="1069" type="multinuc" parent="1068" relname="span"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1071" type="multinuc" parent="1066" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1071" relname="joint"/>
<group id="1074" type="span" parent="74" relname="elaboration"/>
	</body>
</rst>
